Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 51

Sort by

Sort Order Select

Journal Articles

The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria

Blood (2020) 135 (12): 912–920.

https://doi.org/10.1182/blood.2019003399

Published: 2020

Includes: Supplemental data

Journal Articles

Relationship between Pharmacokinetics and Antidrug Antibody Status of ABP 959, a Biosimilar Candidate to Eculizumab: Results from a Pharmacokinetic Similarity Study

Vladimir Hanes, MD, Jean Pan, Daniel T. Mytych, PhD, David Chien, MD, Vincent Chow

Blood (2019) 134 (Supplement_1): 3520.

https://doi.org/10.1182/blood-2019-128621

Published: 2019

Journal Articles

One-Year Efficacy and Safety from a Phase 3 Trial of Ravulizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Receiving Prior Eculizumab Treatment

Austin Kulasekararaj, MDMBBS,MRCP,FRCPath, Anita Hill, MD PhD, Saskia Langemeijer, MD PhD, Richard A. Wells, MD DPhil, F. Ataulfo Gonzalez-Fernandez, Anna Gaya, Emilio Ojeda Gutierrez, Caroline I. Piatek, Lindsay D Mitchell, MBChB, MRCP(UK), FRCPath, Kensuke Usuki, Alberto Bosi, Robert A. Brodsky, MD, Masayo Ogawa, MD FAAP, Ji Yu, Stephan Ortiz, RPh, PhD, Alexander Röth, MD PhD, Jong-Wook Lee, MD PhD, Régis Peffault de Latour, MD PhD

Blood (2019) 134 (Supplement_1): 2231.

https://doi.org/10.1182/blood-2019-128746

Published: 2019

Journal Articles

Clinical Characteristics of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): A Retrospective Chart Review Study

Vladimir Hanes, MD, Jean Pan, Vincent Chow

Blood (2019) 134 (Supplement_1): 4789.

https://doi.org/10.1182/blood-2019-130409

Published: 2019

Journal Articles

Platelet Function in Paroxysmal Nocturnal Haemoglobinuria

Fathima Mohiyaddin Ayyalil, MBBS, FRACP,FRCPA, Samantha J Montague, BSc, PhD, Sarah Hicks, Amandeep Kaur, PhD, Anila Jahangiri, Nalini Pati, MBBS,FRACP,FRCPA, DCH, MD DNB, Philip Crispin, MBBS, FRACP, FRCPA, Yujie Zheng, Xu Tienan, Lucy Coupland, PhDBSc,RN, Woei Ming Lee, James D'Rozario, MBBS, FRACP, FRCPA, Elizabeth E. Gardiner, PhD

Blood (2019) 134 (Supplement_1): 4884.

https://doi.org/10.1182/blood-2019-130291

Published: 2019

Journal Articles

Discordance between Free C5 and CH50 Complement Assays in Measuring Complement C5 Inhibition in Patients with aHUS Treated with Ravulizumab

Spero Cataland, MD, Gema Ariceta, Peter Chen, Bradley Dixon, Katherine Garlo, Laurence Greenbaum, MD PhD, Eric Rondeau, Marie Scully, Stephan Ortiz, RPh, PhD

Blood (2019) 134 (Supplement_1): 1099.

https://doi.org/10.1182/blood-2019-122421

Published: 2019

Journal Articles

Breakthrough Hemolysis in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Ravulizumab: Results of a 52-Week Extension from Two Phase 3 Studies

Anita Hill, MD PhD, Caroline I. Piatek, Régis Peffault de Latour, MD PhD, Lily LL Wong, MD FRCPath, Richard A. Wells, MD DPhil, Robert A. Brodsky, MD, Jin Seok Kim, MD PhD, Junichi Nishimura, MD PhD, Philip Kuriakose, MD, Rodrigo Pavani, Peng Liu, Stephan Ortiz, RPh, PhD, Hubert Schrezenmeier, MD, Jong-Wook Lee, MD PhD, Austin Kulasekararaj, MDMBBS,MRCP,FRCPath

Blood (2019) 134 (Supplement_1): 952.

https://doi.org/10.1182/blood-2019-128929

Published: 2019

Journal Articles

Economic Benefit of Early Inhospital Diagnosis and Treatment Initiation of Eculizumab in aHUS

Bonnie M.K. Donato, PhD, Michael Ryan, MS, William Irish, PhD, Christoph Gasteyger, MD, Gilbert L'Italien, PhD, Jeffrey Laurence, MD

Blood (2018) 132 (Supplement 1): 3565.

https://doi.org/10.1182/blood-2018-99-112893

Published: 2018

Journal Articles

SKY59: A Long-Lasting Engineered Anti-C5 Antibody for Subcutaneously Injectable Anti-Complement Therapy

Kenta Haraya, PhD, Zenjiro Sampei, PhD, Tatsuhiko Tachibana, PhD, Taku Fukuzawa, PhD, Siok Wan Gan, PhD, Meiri Shida-Kawazoe, PhD, Yuichiro Shimizu, PhD, Masaru Muraoka, PhD, Tomoyuki Igawa, PhD, Takehisa Kitazawa, DVM, Junichi Nezu, PhD

Blood (2018) 132 (Supplement 1): 3611.

https://doi.org/10.1182/blood-2018-99-110145

Published: 2018

Journal Articles

Current Status and Optimal Management of Eculizumab Poor-Responders Due to C5 Polymorphisms

Yasutaka Ueda, MD PhD, Hiroyuki Takamori, MD, Jun-Ho Jang, MD PhD, Chezi Ganzel, MD, Saskia Langemeijer, MD PhD, Makiko Osato, MS, Petra Muus, MD PhD, Jong-Wook Lee, MD PhD, Jun-Ichi Nishimura, MD PhD, Yuzuru Kanakura, MD PhD

Blood (2018) 132 (Supplement 1): 2323.

https://doi.org/10.1182/blood-2018-99-111230

Published: 2018

Journal Articles

A Prospective Analysis of Breakthrough Hemolysis in 2 Phase 3 Randomized Studies of Ravulizumab (ALXN1210) Versus Eculizumab in Adults with Paroxysmal Nocturnal Hemoglobinuria

Robert A. Brodsky, MD, Regis Peffault De Latour, Scott T. Rottinghaus, MD, Alexander Röth, MD, Antonio M. Risitano, MD PhD, Ilene C. Weitz, MD, Peter Hillmen, MB ChB, PhD FRCP, FRCPath, Jaroslaw P. Maciejewski, Jeffrey Szer, MBBS, Jong-Wook Lee, MD PhD, Austin G. Kulasekararaj, MBBS, MD MRCP, FRCPath, Lori Volles, MD, Andrew I. Damokosh, PhD, Stephan Ortiz, RPh, PhD, Lori Shafner, PhD, Anita Hill, MD PhS, Hubert Schrezenmeier, MD

Blood (2018) 132 (Supplement 1): 2330.

https://doi.org/10.1182/blood-2018-99-110874

Published: 2018

Journal Articles

Results from a Phase 3, Multicenter, Non-Inferiority Study of Ravulizumab (ALXN1210) Versus Eculizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Currently Treated with Eculizumab

Austin G. Kulasekararaj, MBBS, MD MRCP, FRCPath, Anita Hill, MD PhS, Scott T. Rottinghaus, MD, Saskia Langemeijer, MD PhD, Richard A. Wells, MD DPhil, F. Ataulfo Gonzalez-Fernandez, Anna Gaya, Jong-Wook Lee, MD PhD, Emilio Ojeda Gutierrez, Caroline I. Piatek, Jeffrey Szer, MBBS, Antonio M. Risitano, MD PhD, Shinji Nakao, MD PhD, Eric Bachman, Lori Shafner, PhD, Andrew I. Damokosh, PhD, Stephan Ortiz, RPh, PhD, Alexander Röth, MD, Regis Peffault De Latour

Blood (2018) 132 (Supplement 1): 625.

https://doi.org/10.1182/blood-2018-99-119147

Published: 2018

Journal Articles

Ravulizumab (ALXN1210) Versus Eculizumab in Adults with Paroxysmal Nocturnal Hemoglobinuria: Pharmacokinetics and Pharmacodynamics Observed in Two Phase 3 Randomized, Multicenter Studies

Regis Peffault De Latour, Robert A. Brodsky, MD, Stephan Ortiz, RPh, PhD, Antonio M. Risitano, MD PhD, Jun-Ho Jang, MD PhD, Peter Hillmen, MB ChB, PhD FRCP, FRCPath, Aleksandr Kulagin, Rajendra Pradhan, PhD, Scott T. Rottinghaus, MD, Rasha Aguzzi, MS, Richard A. Wells, MD DPhil, Jeffrey Szer, MBBS

Blood (2018) 132 (Supplement 1): 626.

https://doi.org/10.1182/blood-2018-99-110858

Published: 2018

Journal Articles

A Phase 3 Study of Ravulizumab (ALXN1210) Versus Eculizumab in Adults with Paroxysmal Nocturnal Hemoglobinuria Naive to Complement Inhibitors: Results of a Subgroup Analysis with Patients Stratified By Baseline Hemolysis Level, Transfusion History, and Demographics

Ilene C. Weitz, MD, Aleksandr Kulagin, Shinji Nakao, MD PhD, Caroline I. Piatek, MD, Jeffrey Szer, MBBS, Scott T. Rottinghaus, MD, Lori Volles, MD, Andrew I. Damokosh, PhD, Rasha Aguzzi, MS, Loree Larratt, MD, Antonio M. Risitano, MD PhD

Blood (2018) 132 (Supplement 1): 627.

https://doi.org/10.1182/blood-2018-99-110623

Published: 2018

Journal Articles

Use of Eculizumab in a Patient with Refractory Autoimmune Hemolytic Anemia with Heterozygous NFκB1 Mutation

Katharine Halligan, MD PhD, Lana Vasiljevic, Phillip Roehrs, MD, Andrew Mcginnitie, MD, Sung-Yun Pai, MD, Rachael F. Grace, MD, Maria Olivares Boucher, MD, Lauren Weintraub, MD

Blood (2017) 130 (Supplement 1): 4743.

https://doi.org/10.1182/blood.V130.Suppl_1.4743.4743

Published: 2017

Journal Articles

Coversin, a Novel C5 Complement Inhibitor, Is Safe and Effective in the Treatment of PNH: Results of a Phase II Clinical Trial

Anita Hill, MBChB (Hons), PhD, Wynne Weston-Davies, MB FRCS, Miles Nunn, PhD, Tadeusz Robak, MD PhD, Jerzy Windyga, MD, Andrzej Hellmann, MD PhD DSc, Austin G. Kulasekararaj, MBBS, MD MRCP, FRCPath, Agniezka Piekarska, Anna Szmigielska-Kaplon, Morag Griffin, Talha Munir

Blood (2017) 130 (Supplement 1): 4747.

https://doi.org/10.1182/blood.V130.Suppl_1.4747.4747

Published: 2017

Journal Articles

The SMART-IgG Anti-hC5 Antibody (SKY59/RO7112689) Has Favorable PK, PD, Subcutaneous Bioavailability, and Safety Profile in Phase I HV Study

Alexander Roeth, MD, Nagy Zsolt, MD PhD, Miklos Egyed, MD, Erica Winter, Joy Hsu, Andreas Dieckmann, Judith Anzures-Cabrera, Marie Mannino, Elana Fernandez, PhD, Gregor Jordan, Barbara Klughammer, PhD, Kenji Shinomiya, Naoki Kotani, Ido Paz-Priel, MD, Angelika Jahreis., MD, PhD

Blood (2017) 130 (Supplement 1): 4750.

https://doi.org/10.1182/blood.V130.Suppl_1.4750.4750

Published: 2017

Journal Articles

In Vitro Combination Studies of ACH-4471 with Eculizumab to Assess a Potential "Switch" Treatment Approach for Paroxysmal Nocturnal Hemoglobinuria

Dharaben Patel, MS, Jane A Thanassi, BS, Guangwei Yang, PhD, Xuan Yuan, MD MSc, Robert A. Brodsky, MD, Mingjun Huang, PhD, Steven D Podos, PhD

Blood (2017) 130 (Supplement 1): 2198.

https://doi.org/10.1182/blood.V130.Suppl_1.2198.2198

Published: 2017

Journal Articles

Final Result of a Pilot Study Using Eculizumab to Overcome Platelet Transfusion Refractoriness in Allo-Immunized Patients Receiving HLA Mismatched Platelets

Phuong Vo, Enkhtsetseg Purev, MD PhD, Kamille West, Emily McDuffee, Tatyana Worthy, Lisa Cook, Geri Hawks, Brian Wells, Reem Shalabi, Patricia Prince, Tom Hughes, Willy Fleigel, Sharon Adams, MT, CHS (ABHI), Robert Reger, MS, Xin Tian, PhD, Georg Aue, Richard Childs, MD

Blood (2017) 130 (Supplement 1): 1119.

https://doi.org/10.1182/blood.V130.Suppl_1.1119.1119

Published: 2017

Journal Articles

Optimization of Dose Regimen for ALXN1210, a Novel Complement C5 Inhibitor, in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): Results of 2 Phase 1/2 Studies

Alexander Roeth, MD, Scott T. Rottinghaus, MD, Anita Hill, MBChB (Hons), PhD, Jin Seok Kim, MD PhD, Hubert Schrezenmeier, MD, Louis Terriou, MD, Alvaro Urbano-Ispizua, MD, Richard A. Wells, MD DPhil, Jun Ho Jang, MD PhD, Jeff Szer, MB, BS, FRACP, Rasha Aguzzi, MS, Eric Scott Bachman, MD PhD, Andrew I. Damokosh, PhD, Lori Shafner, PhD, Jong-Wook Lee, MD

Blood (2017) 130 (Supplement 1): 3482.

https://doi.org/10.1182/blood.V130.Suppl_1.3482.3482

Published: 2017

NARROW

The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria

Relationship between Pharmacokinetics and Antidrug Antibody Status of ABP 959, a Biosimilar Candidate to Eculizumab: Results from a Pharmacokinetic Similarity Study

One-Year Efficacy and Safety from a Phase 3 Trial of Ravulizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Receiving Prior Eculizumab Treatment

Clinical Characteristics of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): A Retrospective Chart Review Study

Platelet Function in Paroxysmal Nocturnal Haemoglobinuria

Discordance between Free C5 and CH50 Complement Assays in Measuring Complement C5 Inhibition in Patients with aHUS Treated with Ravulizumab

Breakthrough Hemolysis in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Ravulizumab: Results of a 52-Week Extension from Two Phase 3 Studies

Economic Benefit of Early Inhospital Diagnosis and Treatment Initiation of Eculizumab in aHUS

SKY59: A Long-Lasting Engineered Anti-C5 Antibody for Subcutaneously Injectable Anti-Complement Therapy

Current Status and Optimal Management of Eculizumab Poor-Responders Due to C5 Polymorphisms

A Prospective Analysis of Breakthrough Hemolysis in 2 Phase 3 Randomized Studies of Ravulizumab (ALXN1210) Versus Eculizumab in Adults with Paroxysmal Nocturnal Hemoglobinuria

Results from a Phase 3, Multicenter, Non-Inferiority Study of Ravulizumab (ALXN1210) Versus Eculizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Currently Treated with Eculizumab

Ravulizumab (ALXN1210) Versus Eculizumab in Adults with Paroxysmal Nocturnal Hemoglobinuria: Pharmacokinetics and Pharmacodynamics Observed in Two Phase 3 Randomized, Multicenter Studies

A Phase 3 Study of Ravulizumab (ALXN1210) Versus Eculizumab in Adults with Paroxysmal Nocturnal Hemoglobinuria Naive to Complement Inhibitors: Results of a Subgroup Analysis with Patients Stratified By Baseline Hemolysis Level, Transfusion History, and Demographics

Use of Eculizumab in a Patient with Refractory Autoimmune Hemolytic Anemia with Heterozygous NFκB1 Mutation

Coversin, a Novel C5 Complement Inhibitor, Is Safe and Effective in the Treatment of PNH: Results of a Phase II Clinical Trial

The SMART-IgG Anti-hC5 Antibody (SKY59/RO7112689) Has Favorable PK, PD, Subcutaneous Bioavailability, and Safety Profile in Phase I HV Study

In Vitro Combination Studies of ACH-4471 with Eculizumab to Assess a Potential "Switch" Treatment Approach for Paroxysmal Nocturnal Hemoglobinuria

Final Result of a Pilot Study Using Eculizumab to Overcome Platelet Transfusion Refractoriness in Allo-Immunized Patients Receiving HLA Mismatched Platelets

Optimization of Dose Regimen for ALXN1210, a Novel Complement C5 Inhibitor, in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): Results of 2 Phase 1/2 Studies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only